GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (BSP:S1RP34) » Definitions » Cyclically Adjusted PB Ratio

Sarepta Therapeutics (BSP:S1RP34) Cyclically Adjusted PB Ratio : 12.91 (As of Jun. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sarepta Therapeutics Cyclically Adjusted PB Ratio?

As of today (2024-06-12), Sarepta Therapeutics's current share price is R$33.18. Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was R$2.57. Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is 12.91.

The historical rank and industry rank for Sarepta Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

BSP:S1RP34' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 3.66   Med: 11.6   Max: 38.73
Current: 11.74

During the past years, Sarepta Therapeutics's highest Cyclically Adjusted PB Ratio was 38.73. The lowest was 3.66. And the median was 11.60.

BSP:S1RP34's Cyclically Adjusted PB Ratio is ranked worse than
91.53% of 661 companies
in the Biotechnology industry
Industry Median: 1.67 vs BSP:S1RP34: 11.74

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sarepta Therapeutics's adjusted book value per share data for the three months ended in Mar. 2024 was R$2.533. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is R$2.57 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sarepta Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Cyclically Adjusted PB Ratio Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.13 23.15 10.60 13.55 9.55

Sarepta Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.02 11.40 11.98 9.55 12.52

Competitive Comparison of Sarepta Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PB Ratio falls into.



Sarepta Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sarepta Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=33.18/2.57
=12.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Sarepta Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.533/131.7762*131.7762
=2.533

Current CPI (Mar. 2024) = 131.7762.

Sarepta Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.822 100.560 1.077
201409 0.810 100.428 1.063
201412 0.792 99.070 1.053
201503 0.763 99.621 1.009
201506 0.620 100.684 0.811
201509 0.573 100.392 0.752
201512 0.809 99.792 1.068
201603 0.561 100.470 0.736
201606 0.434 101.688 0.562
201609 1.223 101.861 1.582
201612 1.031 101.863 1.334
201703 1.221 102.862 1.564
201706 1.125 103.349 1.434
201709 1.691 104.136 2.140
201712 2.007 104.011 2.543
201803 1.944 105.290 2.433
201806 1.987 106.317 2.463
201809 1.971 106.507 2.439
201812 2.820 105.998 3.506
201903 3.493 107.251 4.292
201906 2.851 108.070 3.476
201909 2.751 108.329 3.346
201912 2.233 108.420 2.714
202003 3.588 108.902 4.342
202006 3.449 108.767 4.179
202009 3.057 109.815 3.668
202012 2.469 109.897 2.961
202103 1.892 111.754 2.231
202106 1.528 114.631 1.757
202109 1.550 115.734 1.765
202112 3.012 117.630 3.374
202203 2.437 121.301 2.647
202206 2.095 125.017 2.208
202209 1.287 125.227 1.354
202212 1.148 125.222 1.208
202303 1.993 127.348 2.062
202306 1.929 128.729 1.975
202309 2.018 129.860 2.048
202312 2.246 129.419 2.287
202403 2.533 131.776 2.533

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sarepta Therapeutics  (BSP:S1RP34) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sarepta Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (BSP:S1RP34) Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.

Sarepta Therapeutics (BSP:S1RP34) Headlines

No Headlines